Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On (MAGMAAddOn)
Sponsor: Relypsa, Inc.
Terminated
The study could not enroll patients owing to the inclusion exclusion criteria
Other terminated trials from Relypsa, Inc.
More terminations from Relypsa, Inc.
Other Hyperkalemia trials with similar outcome
Listed as NCT03597035, this PHASE4 trial focuses on Hyperkalemia and Type2 Diabetes and remains terminated or withdrawn. Sponsored by Relypsa, Inc., it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Mar 2022 — Jun 2022 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jan 2021 — Mar 2022 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Aug 2018 — Aug 2020 [monthly]
Recruiting PHASE4
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Relypsa, Inc.
- University Hospitals Cleveland Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .